<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021601</url>
  </required_header>
  <id_info>
    <org_study_id>2021-1515</org_study_id>
    <nct_id>NCT05021601</nct_id>
  </id_info>
  <brief_title>Bi-atrial Versus Left Atrial Ablation for Patients With Rheumatic Mitral Valve Disease and Non-paroxysmal Atrial Fibrillation</brief_title>
  <official_title>Bi-atrial Versus Left Atrial Ablation for Patients With Rheumatic Mitral Valve Disease and Non-paroxysmal Atrial Fibrillation: a Multicenter, Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to compare the efficacy of bi-atrial ablation with left atrial ablation&#xD;
      for atrial fibrillation during mitral valve surgery in patients with rheumatic mitral valve&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is present in 40%-60% of patients with rheumatic mitral valve&#xD;
      disease (RMVD), which is an independent predictor of mortality and late stroke. During mitral&#xD;
      valve (MV) surgery, the open left atrium facilitates a bi-atrial ablation procedure. However,&#xD;
      a simplified lesion set including isolated pulmonary vein isolation or posterior left atrial&#xD;
      (LA) wall isolation or LA maze was usually applied. The current literatures provide&#xD;
      insufficient evidence to determine the potential benefits of bi-atrial ablation procedure&#xD;
      when comparing with LA ablation procrdure in patients with non-paroxysmal AF and RMVD.&#xD;
&#xD;
      Patients with RMVD often have longer history, which tends to affect the right atrium,&#xD;
      including pulmonary hypertension or tricuspid regurgitation.The necessity of bi-atrial&#xD;
      ablation procedure targeting the bi-atrial substrate for AF in RMVD requires to be explored.&#xD;
      In this study, we aimed to compare the efficacy of bi-atrial ablation with LA ablation for AF&#xD;
      during MV surgery in patients with RMVD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate without any recurrence of atrial tachyarrhythmias in the absence of antiarrhythmic drugs</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Without detections of atrial fibrillation, atrial flutter, or other atrial tachyarrhythmias with a duration of greater than 30 seconds documented by 3-day Holter monitoring in the absence of antiarrhythmic drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate without permanent pacemaker implantation (Key secondary outcome)</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Percentage of participants who did not have a new permanent pacemaker implanted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate without any recurrence of atrial tachyarrhythmias with antiarrhythmic drugs</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Without detections of atrial fibrillation, atrial flutter, or other atrial tachyarrhythmias with a duration of greater than 30 seconds documented by 3-day Holter monitoring with antiarrhythmic drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of atrial fibrillation</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Burden of atrial fibrillation according to 3-day Holter monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Including cardiac death, stroke, heart failure requiring rehospitalization, embolic events or bleeding events requiring rehospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Measured with questionnaire of Atrial Fibrillation Effect on Quality-of-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Bi-atrial ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive mitral valve surgery concomitant with bi-atrial ablation procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Left atrial ablation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive mitral valve surgery concomitant with left atrial ablation procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bi-atrial ablation</intervention_name>
    <description>This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.</description>
    <arm_group_label>Bi-atrial ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Left atrial ablation</intervention_name>
    <description>This intervention includes mitral valve surgery concomitant with left atrial ablation alone.</description>
    <arm_group_label>Left atrial ablation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Diagnosis of persistent atrial fibrillation(AF) or long-standing persistent AF by&#xD;
             medical history and Holter monitoring (persistent AF lasting more than 7 days;&#xD;
             long-standing persistent AF lasting more than 1 year).&#xD;
&#xD;
          -  Rheumatic mitral valve disease(RMVD) requires mitral valve surgery( RMVD was&#xD;
             determined by history of acute rheumatic fever, valve morphology, echocardiographic&#xD;
             findings and pathological diagnosis).&#xD;
&#xD;
          -  Consent to surgical ablation of AF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal AF&#xD;
&#xD;
          -  Degenerative or ischemic mitral valve disease&#xD;
&#xD;
          -  Evidence of active infection&#xD;
&#xD;
          -  Previous catheter ablation or surgical ablation for AF&#xD;
&#xD;
          -  Surgical management of hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
          -  Absolute contraindications for anticoagulation therapy&#xD;
&#xD;
          -  Left atrial thrombosis (not including left atrial appendage thrombosis alone)&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease(Forced expiratory volume in 1 second (FEV1)&lt;30%&#xD;
             anticipated value)&#xD;
&#xD;
          -  Uncontrolled hypo- or hyperthyroidism&#xD;
&#xD;
          -  Mental impairment or other conditions that may not allow participants to understand&#xD;
             the nature, significance, and scope of study&#xD;
&#xD;
          -  Left atrial diameter&gt;70mm&#xD;
&#xD;
          -  Right ventricular dysfunction (TAPSE&lt;16) or moderate to severe tricuspid regurgitation&#xD;
             or pulmonary artery pressure (estimated by echocardiography) &gt;60mmHg&#xD;
&#xD;
          -  Coronary artery bypass grafting is required for participants with coronary heart&#xD;
             disease&#xD;
&#xD;
          -  Previous cardiac surgery&#xD;
&#xD;
          -  Refuse to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <phone>: +86-010-88396051</phone>
    <email>zhengzhe@fuwai.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haojie Li, MD</last_name>
    <email>lihaojiefuwai@126.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatic mitral valve disease</keyword>
  <keyword>Surgical ablation</keyword>
  <keyword>Mitral valve surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

